# US 2019/0375739 A1 · Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375739 A1
- Document ID: US20190375739A1
- Status: Published application
- Kind: A1
- Application number: 16/239,836
- Filed: 2019-01-04
- Published: 2019-12-12
- Earliest claimed: 2008-07-10
- Assignees: Angion Biomedica Corp.
- Applicants: Angion Biomedica Corp.
- Inventors: Weizhong Cai; Prakash Narayan; Bijoy Panicker; David E. Smith
- Web page: https://patentgrep.com/patent/US20190375739A1

## CPC

- C07D 409/14: containing three or more hetero rings
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/145: {with organic compounds}
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/415: 1,2-Diazoles
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/32: Alcohol-abuse
- A61P 31/14: for RNA viruses
- A61P 31/20: for DNA viruses
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/14: containing three or more hetero rings
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compositions and formulations of compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein p, R1, R2 and B are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of injuries, conditions or diseases in which HGF/SF or the activities thereof, or agonists or antagonists thereof have a therapeutically useful role. In addition, methods are provided for treating such diseases or diseases starting at a time after the onset of the injury, condition or disease.

## Claims

### Claim at position 1

1-47. (canceled)

### Claim 48

A method of administering a therapeutically effective amount of a compound of Formula (A):
or a tautomer thereof,
or a pharmaceutically acceptable salt thereof,
wherein:
C═C is cis or trans;
A represents an optionally substituted aromatic or non-aromatic 5-6 membered monocyclic ring, optionally containing 1-4 heteroatoms selected from N, O or S; or an optionally substituted aromatic or non-aromatic 8-12 membered bicyclic ring, optionally containing 1-6 heteroatoms selected from N, O or S;
q is 1 or 2;
each R is independently selected from the group consisting of hydrogen, halogen, hydroxyl, —NO2, —CN, an optionally substituted aliphatic, heteroaliphatic, aromatic, or heteroaromatic moiety, —ORR, —S(═O)nRd, —NRbRc, and —C(═O)Ra;
n is 0, 1, or 2;
each RR is independently an optionally substituted aliphatic, heteroaliphatic, aromatic, or heteroaromatic moiety;
Ra, at each occurrence, is independently selected from the group consisting of hydrogen, hydroxy, and an optionally substituted aliphatic, heteroaliphatic, aryl, or heteroaryl;
Rb and Rc, at each occurrence, are independently selected from the group consisting of hydrogen, hydroxyl, SO2Rd, and optionally substituted aliphatic, heteroaliphatic, aryl, or heteroaryl;
Rd, at each occurrence, is independently selected from the group consisting of hydrogen, —N(Re)2, and optionally substituted aliphatic, aryl, or heteroaryl; and
Re, at each occurrence, is independently hydrogen or optionally substituted aliphatic,
the method comprising administering a pharmaceutical composition comprising the compound of Formula (A) in aqueous buffered saline containing about 40% to about 60% (v/v) polyethylene glycol 300 and about 5% to about 15% polysorbate 80.

### Claim 49 (depends on 48)

The method of claim 48, wherein the composition comprises the compound of Formula (A) in aqueous buffered saline containing about 50% (v/v) polyethylene glycol 300 and about 10% (v/v) polysorbate 80.

### Claim 50 (depends on 48)

The method of claim 48, wherein the composition comprises about 0.8 mg/mL to about 10 mg/mL of the compound of Formula (A).

### Claim 51 (depends on 48)

The method of claim 48, wherein the pH of the composition is about 7.4.

### Claim 52 (depends on 48)

The method of claim 48, wherein the compound of Formula (A) is:
wherein RN is hydrogen, alkyl, heteroalkyl, aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, acyl, or a nitrogen protecting group.

### Claim 53 (depends on 48)

The method of claim 48, wherein the compound of Formula (A) is selected from:
(E)-3 (5)-[2-(2,3-methylenedioxyphenyl)vinyl]-1H-pyrazole,
(Z)-3 (5)-[2-(2,3-methylenedioxyphenyl)vinyl]-1H-pyrazole,
(E)-3 (5)-[2-(2-chloro-5-trifluoromethylphenyl)vinyl]-1H-pyrazole,
(Z)-3 (5)-[2-(2-chloro-5-trifluoromethylphenyl)vinyl]-1H-pyrazole,
(E)-3 (5)-[2-(2-trifluoromethylphenyl)vinyl]-1H-pyrazole,
(Z)-3 (5)-[2-(2-trifluoromethylphenyl)vinyl]-1H-pyrazole,
(E)-3 (5)-[2-(2-furyl)vinyl]-1H-pyrazole,
(Z)-3 (5)-[2-(2-furyl)vinyl]-1H-pyrazole,
(E)-3 (5)-[2-(2-thienyl)vinyl]-1H-pyrazole,
(Z)-3 (5)-[2-(2-thienyl)vinyl]-1H-pyrazole,
(E)-3-(2-(5-nitrofuran-2-yl)vinyl)-1H-pyrazole,
(Z)-3-(2-(5-nitrofuran-2-yl)vinyl)-1H-pyrazole,
(E)-3-styryl-1H-pyrazole,
(Z)-3-styryl-1H-pyrazole,
(E)-2-(2-(1H-pyrazol-3-yl)vinyl)-1H-indole,
(Z)-2-(2-(1H-pyrazol-3-yl)vinyl)-1H-indole,
(E)-4-(2-(1H-pyrazol-3-yl)vinyl)-N,N-dimethylaniline,
(Z)-4-(2-(1H-pyrazol-3-yl)vinyl)-N,N-dimethylaniline,
(E)-3-(4-methoxystyryl)-1H-pyrazole,
(Z)-3-(4-methoxystyryl)-1H-pyrazole,
(E)-3-(2,6-dichlorostyryl)-1H-pyrazole,
(Z)-3-(2,6-dichlorostyryl)-1H-pyrazole,
(E)-3-(2-(naphthalen-2-yl)vinyl)-1H-pyrazole,
(Z)-3-(2-(naphthalen-2-yl)vinyl)-1H-pyrazole,
(E)-3-(2-(1H-pyrrol-2-yl)vinyl)-1H-pyrazole,
(Z)-3-(2-(1H-pyrrol-2-yl)vinyl)-1H-pyrazole,
(E)-3-(2-(thiophen-3-yl)vinyl)-1H-pyrazole,
(Z)-3-(2-(thiophen-3-yl)vinyl)-1H-pyrazole,
(E)-3-(2-(1H-pyrrol-3-yl)vinyl)-1H-pyrazole,
(Z)-3-(2-(1H-pyrrol-3-yl)vinyl)-1H-pyrazole,
(E)-3-(2-(furan-3-yl)vinyl)-1H-pyrazole, and
(Z)-3-(2-(furan-3-yl)vinyl)-1H-pyrazole,
or a pharmaceutically acceptable salt thereof.

### Claim 54

A method of treating or lessening the severity of a disease, disorder, or condition selected from ischemic heart disease, damaged and/or ischemic organs, transplants or grafts, ischemia/reperfusion injury, myocardial ischemia, renal failure, renal fibrosis, idiopathic pulmonary fibrosis, vascularization of a damaged and/or ischemic organ, transplant or graft, amelioration of ischemia/reperfusion injury in the kidney, normalization of myocardial perfusion as a consequence of myocardial infarction, fibrosis secondary to renal obstruction, renal trauma and transplantation, and renal failure secondary to chronic diabetes or hypertension,
comprising administering a pharmaceutical composition comprising a compound of Formula (A):
or a tautomer thereof,
or a pharmaceutically acceptable salt thereof,
wherein:
C═C is cis or trans;
A represents an optionally substituted aromatic or non-aromatic 5-6 membered monocyclic ring, optionally containing 1-4 heteroatoms selected from N, O or S; or an optionally substituted aromatic or non-aromatic 8-12 membered bicyclic ring, optionally containing 1-6 heteroatoms selected from N, O or S;
q is 1 or 2;
each R is independently selected from the group consisting of hydrogen, halogen, hydroxyl, —NO2, —CN, an optionally substituted aliphatic, heteroaliphatic, aromatic, or heteroaromatic moiety, —ORR, —S(═O)nRd, —NRbRc, and —C(═O)Ra;
n is 0, 1, or 2;
each RR is independently an optionally substituted aliphatic, heteroaliphatic, aromatic, or heteroaromatic moiety;
Ra, at each occurrence, is independently selected from the group consisting of hydrogen, hydroxy, and an optionally substituted aliphatic, heteroaliphatic, aryl, or heteroaryl;
Rb and Rc, at each occurrence, are independently selected from the group consisting of hydrogen, hydroxyl, SO2Rd, and optionally substituted aliphatic, heteroaliphatic, aryl, or heteroaryl;
Rd, at each occurrence, is independently selected from the group consisting of hydrogen, —N(Re)2, and optionally substituted aliphatic, aryl, or heteroaryl; and
Re, at each occurrence, is independently hydrogen or optionally substituted aliphatic,
in aqueous buffered saline containing about 40% to about 60% (v/v) polyethylene glycol 300 and about 5% to about 15% polysorbate 80.

### Claim 55 (depends on 54)

The method of claim 54, wherein pharmaceutical composition is administered at least 3 hours after the onset of the disease, disorder, or condition.

### Claim 56 (depends on 55)

The method of claim 55, wherein pharmaceutical composition is administered at least 24 hours after the onset of the disease, disorder, or condition.

### Claim 57 (depends on 54)

The method of claim 54, wherein the pharmaceutical composition is administered so that peak or near peak circulating levels of the compound of Formula (A) are present at the peak or near expression of c-Met.

### Claim 58 (depends on 54)

The method of claim 54, wherein the composition comprises the compound of Formula (A) in aqueous buffered saline containing about 50% (v/v) polyethylene glycol 300 and about 10% (v/v) polysorbate 80.

### Claim 59 (depends on 54)

The method of claim 54, wherein the composition comprises about 0.8 mg/mL to about 10 mg/mL of the compound of Formula (A).

### Claim 60 (depends on 54)

The method of claim 54, wherein the pH of the composition is about 7.4.

### Claim 61 (depends on 54)

The method of claim 54, wherein the compound of Formula (A) is:
wherein RN is hydrogen, alkyl, heteroalkyl, aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, acyl, or a nitrogen protecting group.

### Claim 62 (depends on 54)

The method of claim 54, wherein the compound of Formula (A) is selected from:
(E)-3 (5)-[2-(2,3-methylenedioxyphenyl)vinyl]-1H-pyrazole,
(Z)-3 (5)-[2-(2,3-methylenedioxyphenyl)vinyl]-1H-pyrazole,
(E)-3 (5)-[2-(2-chloro-5-trifluoromethylphenyl)vinyl]-1H-pyrazole,
(Z)-3 (5)-[2-(2-chloro-5-trifluoromethylphenyl)vinyl]-1H-pyrazole,
(E)-3 (5)-[2-(2-trifluoromethylphenyl)vinyl]-1H-pyrazole,
(Z)-3 (5)-[2-(2-trifluoromethylphenyl)vinyl]-1H-pyrazole,
(E)-3 (5)-[2-(2-furyl)vinyl]-1H-pyrazole,
(Z)-3 (5)-[2-(2-furyl)vinyl]-1H-pyrazole,
(E)-3 (5)-[2-(2-thienyl)vinyl]-1H-pyrazole,
(Z)-3 (5)-[2-(2-thienyl)vinyl]-1H-pyrazole,
(E)-3-(2-(5-nitrofuran-2-yl)vinyl)-1H-pyrazole,
(Z)-3-(2-(5-nitrofuran-2-yl)vinyl)-1H-pyrazole,
(E)-3-styryl-1H-pyrazole,
(Z)-3-styryl-1H-pyrazole,
(E)-2-(2-(1H-pyrazol-3-yl)vinyl)-1H-indole,
(Z)-2-(2-(1H-pyrazol-3-yl)vinyl)-1H-indole,
(E)-4-(2-(1H-pyrazol-3-yl)vinyl)-N,N-dimethylaniline,
(Z)-4-(2-(1H-pyrazol-3-yl)vinyl)-N,N-dimethylaniline,
(E)-3-(4-methoxystyryl)-1H-pyrazole,
(Z)-3-(4-methoxystyryl)-1H-pyrazole,
(E)-3-(2,6-dichlorostyryl)-1H-pyrazole,
(Z)-3-(2,6-dichlorostyryl)-1H-pyrazole,
(E)-3-(2-(naphthalen-2-yl)vinyl)-1H-pyrazole,
(Z)-3-(2-(naphthalen-2-yl)vinyl)-1H-pyrazole,
(E)-3-(2-(1H-pyrrol-2-yl)vinyl)-1H-pyrazole,
(Z)-3-(2-(1H-pyrrol-2-yl)vinyl)-1H-pyrazole,
(E)-3-(2-(thiophen-3-yl)vinyl)-1H-pyrazole,
(Z)-3-(2-(thiophen-3-yl)vinyl)-1H-pyrazole,
(E)-3-(2-(1H-pyrrol-3-yl)vinyl)-1H-pyrazole,
(Z)-3-(2-(1H-pyrrol-3-yl)vinyl)-1H-pyrazole,
(E)-3-(2-(furan-3-yl)vinyl)-1H-pyrazole, and
(Z)-3-(2-(furan-3-yl)vinyl)-1H-pyrazole,
or a pharmaceutically acceptable salt thereof.

### Claim 63

A method of preparing a pharmaceutical composition comprising a compound of Formula (A):
or a tautomer thereof,
or a pharmaceutically acceptable salt thereof,
wherein:
C═C is cis or trans;
A represents an optionally substituted aromatic or non-aromatic 5-6 membered monocyclic ring, optionally containing 1-4 heteroatoms selected from N, O or S; or an optionally substituted aromatic or non-aromatic 8-12 membered bicyclic ring, optionally containing 1-6 heteroatoms selected from N, O or S;
q is 1 or 2;
each R is independently selected from the group consisting of hydrogen, halogen, hydroxyl, —NO2, —CN, an optionally substituted aliphatic, heteroaliphatic, aromatic, or heteroaromatic moiety, —ORR, —S(═O)nRd, —NRbRb, and —C(═O)Ra;
n is 0, 1, or 2;
each RR is independently an optionally substituted aliphatic, heteroaliphatic, aromatic, or heteroaromatic moiety;
Ra, at each occurrence, is independently selected from the group consisting of hydrogen, hydroxy, and an optionally substituted aliphatic, heteroaliphatic, aryl, or heteroaryl;
Rb and Rc, at each occurrence, are independently selected from the group consisting of hydrogen, hydroxyl, SO2Rd, and optionally substituted aliphatic, heteroaliphatic, aryl, or heteroaryl;
Rd, at each occurrence, is independently selected from the group consisting of hydrogen, —N(Re)2, and optionally substituted aliphatic, aryl, or heteroaryl; and
Re, at each occurrence, is independently hydrogen or optionally substituted aliphatic,
the method comprising (i) providing a composition of the compound of Formula (A); and (ii) formulating the composition in aqueous buffered saline containing about 40% to about 60% (v/v) polyethylene glycol 300 and about 5% to about 15% polysorbate 80.

### Claim 64 (depends on 63)

The method of claim 63, wherein the pharmaceutical composition is an injectable pharmaceutical composition.

### Claim 65 (depends on 64)

The method of claim 64, wherein the injectable pharmaceutical composition is sterile.

### Claim 66 (depends on 63)

The method of claim 63, wherein the compound has a solubility in the composition of about 0.8 mg/mL to about 10 mg/mL.

### Claim 67 (depends on 63)

The method of claim 63, wherein the composition comprises the compound of Formula (A) in aqueous buffered saline containing about 50% (v/v) polyethylene glycol 300 and about 10% (v/v) polysorbate 80.

### Claim 68 (depends on 63)

The method of claim 63, wherein the composition comprises about 0.8 mg/mL to about 10 mg/mL of the compound of Formula (A).

### Claim 69 (depends on 63)

The method of claim 63, wherein the pH of the composition is about 7.4.

### Claim 70 (depends on 63)

The method of claim 63, wherein the compound of Formula (A) is:
wherein RN is hydrogen, alkyl, heteroalkyl, aryl, heteroaryl, -(alkyl)aryl, -(alkyl)heteroaryl, acyl, or a nitrogen protecting group.

### Claim 71 (depends on 63)

The method of claim 63, wherein the compound of Formula (A) is selected from:
(E)-3 (5)-[2-(2,3-methylenedioxyphenyl)vinyl]-1H-pyrazole,
(Z)-3 (5)-[2-(2,3-methylenedioxyphenyl)vinyl]-1H-pyrazole,
(E)-3 (5)-[2-(2-chloro-5-trifluoromethylphenyl)vinyl]-1H-pyrazole,
(Z)-3 (5)-[2-(2-chloro-5-trifluoromethylphenyl)vinyl]-1H-pyrazole,
(E)-3 (5)-[2-(2-trifluoromethylphenyl)vinyl]-1H-pyrazole,
(Z)-3 (5)-[2-(2-trifluoromethylphenyl)vinyl]-1H-pyrazole,
(E)-3 (5)-[2-(2-furyl)vinyl]-1H-pyrazole,
(Z)-3 (5)-[2-(2-furyl)vinyl]-1H-pyrazole,
(E)-3 (5)-[2-(2-thienyl)vinyl]-1H-pyrazole,
(Z)-3 (5)-[2-(2-thienyl)vinyl]-1H-pyrazole,
(E)-3-(2-(5-nitrofuran-2-yl)vinyl)-1H-pyrazole,
(Z)-3-(2-(5-nitrofuran-2-yl)vinyl)-1H-pyrazole,
(E)-3-styryl-1H-pyrazole,
(Z)-3-styryl-1H-pyrazole,
(E)-2-(2-(1H-pyrazol-3-yl)vinyl)-1H-indole,
(Z)-2-(2-(1H-pyrazol-3-yl)vinyl)-1H-indole,
(E)-4-(2-(1H-pyrazol-3-yl)vinyl)-N,N-dimethylaniline,
(Z)-4-(2-(1H-pyrazol-3-yl)vinyl)-N,N-dimethylaniline,
(E)-3-(4-methoxystyryl)-1H-pyrazole,
(Z)-3-(4-methoxystyryl)-1H-pyrazole,
(E)-3-(2,6-dichlorostyryl)-1H-pyrazole,
(Z)-3-(2,6-dichlorostyryl)-1H-pyrazole,
(E)-3-(2-(naphthalen-2-yl)vinyl)-1H-pyrazole,
(Z)-3-(2-(naphthalen-2-yl)vinyl)-1H-pyrazole,
(E)-3-(2-(1H-pyrrol-2-yl)vinyl)-1H-pyrazole,
(Z)-3-(2-(1H-pyrrol-2-yl)vinyl)-1H-pyrazole,
(E)-3-(2-(thiophen-3-yl)vinyl)-1H-pyrazole,
(Z)-3-(2-(thiophen-3-yl)vinyl)-1H-pyrazole,
(E)-3-(2-(1H-pyrrol-3-yl)vinyl)-1H-pyrazole,
(Z)-3-(2-(1H-pyrrol-3-yl)vinyl)-1H-pyrazole,
(E)-3-(2-(furan-3-yl)vinyl)-1H-pyrazole, and
(Z)-3-(2-(furan-3-yl)vinyl)-1H-pyrazole,
or a pharmaceutically acceptable salt thereof.
